protein-viscosity-reduction-strategies
Getting from a molecule to medicine is harder than ever, especially with complex issues like protein viscosity. Discover how a true partnership can de-risk your drug product development and accelerate your program.
Menu
FAQ
Current Situation
Typical Market Trends
Current Challenges and How They Are Solved
How Leukocare Can Support These Challenges
Value Provided to Customers
The Formulation Challenge: Finding a True Partner in Drug Product Development
Getting from a molecule to a medicine is harder than ever. Teams across the biopharmaceutical industry, from virtual biotechs to large pharma, face constant pressure. You need to move faster, work with new and challenging types of drugs, and build partnerships that truly speed up your program. The goal isn't just to find a vendor to check a box; it's about finding a partner who thinks with you, anticipates problems, and helps make the journey less risky from the very beginning.
This article looks at the current situation for drug product development, the challenges leaders in Chemistry, Manufacturing, and Controls (CMC) and Drug Product (DP) roles face, and how a different kind of partnership can change things.
Current Situation
The biopharma industry is growing, with the contract manufacturing market alone projected to expand significantly, reaching over USD 34 billion by 2030 [1]. This growth is fueled by the increasing complexity of biologics and the need for specialized expertise that many companies choose not to build in-house [2, 3]. We see this every day in our work with clients.
There are fast-track virtual biotechs, backed by solid funding, who need to get to a Biologics License Application (BLA) as quickly and cleanly as possible. Then there are small, early-stage biotechs with experienced leadership but no internal labs, looking for a secure path to an Investigational New Drug (IND) application.
Large pharmaceutical companies are working with new modalities like viral vectors and RNA, where internal teams might not have much experience with them [21, 4]. Mid-size biotechs often have established internal DP teams but run into capacity or specific knowledge limits when faced with a difficult project [5]. Contract Development and Manufacturing Organizations (CDMOs) are more and more asked by their clients for formulation services, creating a need for trusted, neutral partners who can fit in seamlessly.
Typical Market Trends
Several trends define the current market. Outsourcing R&D and manufacturing continues to be a main way to save money and get special skills [7]. The biopharmaceutical contract manufacturing market is expected to grow at a compound annual growth rate (CAGR) of 8.8% between 2025 and 2030 [1]. This isn't just about capacity; it's about capability.
The nature of the drugs themselves is changing. Advanced therapies like monoclonal antibodies, cell and gene therapies, and RNA-based medicines create unique problems for stability and delivery, so new formulation methods are needed [4, 8, 9, 21]. These complex molecules are sensitive to environmental factors and require careful handling to maintain their structure and function [10, 11, 12].
Technology is playing a much larger role. The digitalization of CMC is picking up speed, with AI and predictive modeling being used to make processes better, predict manufacturing problems, and make decisions faster [13, 14, 15]. These tools can analyze vast datasets to make development less risky and find the best formulation plans a lot faster than old ways [15, 16, 17, 29]. This shift is also changing partnership models, moving them from simple, fee-for-service arrangements to more strategic, collaborative alliances where risk and reward are shared [19, 20, 6].
Current Challenges and How They Are Solved
Across different company types and sizes, leaders in drug product development face a common set of hurdles.
Intense Pressure for Speed and Perfection: For a well-funded biotech on a fast track, there is no room for mistakes. The board has high expectations, timelines are aggressive, and any misstep can be costly. This pressure is made worse by a healthy skepticism of service providers who don't think strategically and only offer quick fixes. The solution isn't just hiring another pair of hands. It's about finding a strategic co-pilot, a partner who understands the stakes, brings their own informed opinions, and collaborates on a level of shared ownership.
Navigating Uncharted Scientific Territory: Large pharma companies moving into new modalities like ADCs or viral vectors often face internal uncertainty. Their existing teams and resources are strong, but experience gaps in these new areas can slow things down. They often find that vendors offer generic, templated solutions that don't address the unique challenges of the new molecule. What they really need are specific insights, deep technical know-how for that modality, and a real thought partner to help navigate internal discussions and make development less risky.
The Partnership Puzzle: Finding the right external partners is a constant challenge. Small biotechs may have had bad experiences with providers who are too academic and not focused enough on practical, timely solutions. Mid-size companies often find their internal processes for onboarding new vendors are slow and rigid, making it difficult to bring in specialists for a unique challenge. For CDMOs, the risk is that an external formulation partner may act unprofessionally or too independently, creating issues with the end client. Solving this requires partners who are proactive, communicate clearly, and can deliver dependable results with minimal overhead [4, 21, 23, 24]. For CDMOs, it means finding a partner who can work discreetly in the background.
Bandwidth and Resource Constraints: For small and mid-size biotechs, internal capacity is often the biggest bottleneck. Teams are busy, and there isn't enough time or material to run extensive experiments. These companies need external partners who can operate independently, think proactively to reduce the internal workload, and deliver structured, reliable data that builds a strong CMC story for investors and regulators [20, 22].
How Leukocare Can Support These Challenges
Our approach is designed around these very challenges. We built our services to function as a strategic partner, not just a service provider, to address the core needs of drug product development leaders.
For the Fast-Track Biotech Leader, we provide more than just data. We use our Smart Formulation Platform, which incorporates AI-based stability prediction, to design data-driven, regulatory-sound formulations tailored to aggressive timelines. Our claim is simple: "We help you reach BLA faster—with a formulation designed by science, guided by data, and built for regulatory success."
For the Small Biotech with limited resources, we offer a clear path forward when time and materials are scarce. We provide proactive ideas, structured processes, and clear documentation aligned with investor and regulatory needs. We deliver on our promise: "We give you structure, speed, and substance—driven by data, and delivered with reliability."
For the Mid-size Biotech needing to break in a new partner, we make it easy to get started. We often begin with a specific, complex problem—like a new modality or a lyostability issue—and run a pilot project. This allows us to prove our value on a small scale before expanding. Our claim is a call to action: "Let us solve one complex problem—using our modeling platform and formulation intelligence to deliver results you can trust."
For the Pharma company tackling a new modality, we provide the deep, specific technical knowledge they need. We don't use generic templates. We offer mini-workshops and tailored support materials to act as a true sparring partner. Our commitment is: "We don't pitch templates—we guide your modality path with real data, real expertise, and tailored formulation design."
For the CDMO seeking a network partner, we function as a silent, seamless extension of their team. We handle projects independently, maintain loyalty to the CDMO relationship without client poaching, and adapt to their workflow. We act on our claim: "We act as your formulation team—silent, seamless, and science-backed—always loyal to your client relationship."
Value Provided to Customers
Our goal is to deliver real value that moves projects forward. We do this in three key ways:
Making Development Less Risky. By using predictive modeling and deep formulation experience, we provide data-backed insights that support internal decision-making and make the development of new and complex modalities less risky. We create reliable, strong formulations that are built for regulatory success from the start [21, 23, 24].
Speeding Up Timelines. Our entire approach is built for speed and efficiency. By making all CMC parts work together at the same time and using predictive tools to find the best path forward, we help our clients get to IND and BLA faster. This is really important for companies with fast-track designation [25, 26, 27].
Being a True Strategic Partner. We move beyond a simple vendor relationship. Whether that's hands-on support for a small biotech or acting as a discreet, low-maintenance partner for a CDMO, we deliver data-informed, reliable results. We provide the structure, speed, and substance our partners need to succeed.
FAQ
Q1: We are a virtual biotech under immense pressure to get to BLA. How can a formulation partner do more than just execute tasks?
A partner should act as a strategic co-pilot. This means not only doing what's planned but actively helping with proactive, solution-oriented ideas. They should bring scientific excellence, deep regulatory know-how, and the ability to work as peers with your CMC professionals. The focus should be on forward-thinking collaboration that sees problems coming and makes a smooth, fast path to your goal.
Q2: Our internal drug product team is good but busy, especially with new modalities. How can we bring in specialized expertise without disrupting our existing vendor relationships and processes?
The best way is to start with a specific, clear challenge where you have a definite need—a pilot project. This could be a new, difficult modality or a stability issue with an existing product. This approach allows you to test a new partner on a contained project, proving their value without causing issues or making your team feel like they're being ignored. The right partner will focus on supporting your team, not replacing them, and delivering results that make everyone successful.
Q3: We're a CDMO, and our clients are asking more and more for formulation services. How can we offer this without building an internal team and ensuring the partner relationship is seamless and discreet?
You need a partner who understands their role is to support your client relationship, not compete with it. Look for a partner who can work on their own without needing you to coordinate a lot. They should be adaptable, practical, and committed to loyalty, meaning they won't try to steal your clients. The ideal partner blends into the background, acting as a silent, science-backed extension of your own team.
Q4: How does predictive modeling actually make our formulation development less risky in the real world?
Predictive modeling, when used with AI, uses large datasets to predict how a molecule will act under different conditions and with different excipients. This allows for a much more focused and effective development process [17, 29]. Instead of just doing a lot of trial-and-error experiments, which take time and cost a lot for materials, you can do computer simulations to find the most promising formulation options early on. This gives insights based on data that help with decisions, helping you create a more stable, effective, and strong formulation faster and with greater confidence [15, 16].
